I believe Cyclin-Dependent Kinase 9 (CDK9) inhibitors are one modality that will bring us a step closer to that future. By targeting the fundamental processes that enable cancer cell survival ...

Prelude’s CEO, Kris Vaddi, Ph.D., emphasized the significance of PRT2527’s results while outlining future priorities. “These findings confirm our hypothesis that a selective and potent CDK9 ...

本文来自药明康德内容微信团队，欢迎转发到朋友圈，谢绝转载到其他平台。如有开设白名单需求，请在“学术经纬”公众号 ...

The company is also advancing SLS009, a small molecule CDK9 inhibitor with promising potential in treating acute myeloid leukemia. The press release includes forward-looking statements regarding ...

The major focus of our research is on the HIV Tat protein, which is essential for HIV transcription, and on two cellular factors, cyclin T1 and Cdk9, which are necessary for Tat function. We are ...